In medical device manufacturing, an implantable catheter must simultaneously achieve sterility, biocompatibility with human tissue, and reliable adhesion to other components. Conventional wet-chemical methods either carry high residue risks or alter the bulk properties of the polymer substrate. Low-temperature plasma offers a clean alternative: by precisely tuning the process gas mixture—O₂, Ar, N₂—specific functional groups can be grafted onto polyurethane or silicone surfaces. Oxygen-containing moieties promote cell adhesion, while fluorinated groups impart anti-fouling properties. The entire process is dry, non-destructive, and fully traceable.
In semiconductor packaging, wire bonding is a critical step. Nanoscale oxide layers or organic residues on bond pads directly compromise bond strength. Hydrogen-based or argon–hydrogen plasmas reduce oxides and remove photoresist residues without damaging fine metal interconnects. This is not a lab curiosity—it is already a standard process on advanced assembly lines.
What unites these two industries is a zero-tolerance policy for trial and error; they adopt only proven, production-validated solutions.
That is precisely why companies like TE Connectivity, Huawei, Amphenol, Sunny Optical, and WLCSP have chosen PLAUX for their plasma surface treatment needs. Not because the names carry weight, but because PLAUX has accumulated extensive production-grade experience across both low-pressure vacuum and atmospheric-pressure plasma technologies—from hydrophilic modification of medical catheters, to oxide removal prior to wire bonding, to online activation of PP materials for automotive lighting. Each application is a mature, high-volume, long-term stable process already running on real production floors.
